Understanding HER2-low and HER2-ultralow classification in mBC

In this video podcast moderated by the Oncology Brothers, Dr Komal Jhaveri provides a practical overview of how this shift beyond a binary HER2 model translates into everyday clinical practice.

The experts explore:

• Key efficacy data from DESTINY-Breast04 and DESTINY-Breast06, and their impact on the HER2 treatment framework
• The clinical relevance of HER2-low and HER2-ultralow categories, and review the CAP reporting template
• When and why to perform re-biopsy to detect changes in HER2 expression over time
• Best practices for monitoring and managing T-DXd–related adverse events, including nausea, vomiting, fatigue and ILD/pneumonitis

Watch now to deepen your understanding of HER2-low and HER2-ultralow classification, refine how and when you test, and appreciate the impact on therapeutic decision-making in mBC.

Clinical takeaways

• DESTINY-Breast04 and DESTINY-Breast-06 established T-DXd as an effective option for HER2-low and HER2-ultralow mBC, improving PFS and OS and showing that even minimal HER2 expression can identify patients who benefit from T-DXd
• Current CAP reporting template separates HER2-low (IHC 1+ or 2+/ISH–) and HER2-ultralow (IHC 0 with faint or incomplete membrane staining in ≤10% of tumour cells) from true HER2-0, creating treatment-defining strata for HER2-targeted ADCs such as T-DXd
• Because HER2 expression is dynamic between primary and metastatic sites and over time, re-biopsy at progression, particularly in tumours previously scored as HER2-0, should be considered to identify new candidates for T-DXd
• T-DXd delivers substantial antitumour activity, but treatment-related adverse events, including nausea, vomiting, fatigue, alopecia and, in particular, ILD/pneumonitis, require careful and proactive management. Clinicians should apply structured supportive care and early, vigilant monitoring to ensure safe and sustained treatment

This is the full video. Watch the shorter highlights video here: https://youtu.be/3xepcF70Ljw

Listen to the audio version of this conversation on Spotify, Apple, or on the COR2ED website

Follow us on social media:

LinkedIn: https://www.linkedin.com/company/breastcancerconnect/

X: https://x.com/BreastCaConnect

This content is intended for healthcare professionals only.

This programme is supported by an Independent Education Grant from AstraZeneca.

This podcast is developed by cor2ed.com

Published December 2025

Subscribe to this channel to stay up to date with new Independent Education programmes as they’re released.

In this podcast, Medical Oncologist, Dr Aman Chauhan and Neuroendocrine Patient Advocate, Susan Meckler-Plummer, discuss extrapulmonary high-grade neuroendocrine carcinomas (EP-NECs), a rare, aggressive, and often misunderstood subset of neuroendocrine cancers.

They clarify the crucial differences between NETs and NECs, explain why accurate classification and rapid treatment are essential, and highlight current and emerging therapeutic approaches, including DLL3-targeted therapies.

Through both HCP and patient-centred perspectives, the conversation addresses real-world challenges, the importance of support networks, and the growing sense of hope for people affected by this difficult disease.

Key clinical takeaways:

• Unlike NETs, EP-NECs are poorly differentiated, high-grade, aggressive, and fast-growing cancers, with a need for more effective treatments

• While there remains a medical need for effective treatment of EP-NECs, clinical studies with DLL3-targeted agents show promise

• Accessing a support network can provide emotional reinforcement and information for patients and their care partners

You can also watch a video of the experts in conversation and download the accompanying transcript on our website: https://cor2ed.com/net-connect/programmes/ep-nec-diagnosis-treatment-support/?media=0

Or watch on YouTube: https://youtu.be/nfng2s3jSw8

Follow us on social media:

LinkedIn: https://www.linkedin.com/company/cor2ed-net-connect/?viewAsMember=true

X:https://x.com/net_connectinfo

This podcast is supported by an Independent Education Grant from Boehringer Ingelheim.

This podcast is developed by cor2ed.com

Published in November 2025

Subscribe to this channel to stay up to date with new Independent Education programmes as they’re released.

How are advances in radioligand therapy shaping the treatment of neuroendocrine tumours, and what does recent trial evidence tell us? What are the key considerations for patient selection, sequencing, and safety?

In this podcast moderated by the Oncology Brothers, Drs Rohit and Rahul Gosain are joined by medical oncologist Dr Heloisa Soares and nuclear medicine physician Prof. Ken Herrmann to explore the evolving role of targeted radioligand therapy in NETs.

As the conversation unfolds, the experts discuss evidence from recent studies, including the COMPETE trial, share practical insights on multidisciplinary decision-making, and highlight future directions such as the potential for first-line treatment with radioligand therapy.

Key clinical takeaways:

• Pair the right patient with the right treatment using an understanding of the key clinical studies

• The role of PRRT as a very effective 2nd-line treatment was consolidated by the COMPETE study data

• The best outcomes are achieved through multi-disciplinary collaborations that include the patient

Listen to the audio version of this conversation on Spotify, Apple, or on the COR2ED website, where you can also download the accompanying transcript and infographic: https://cor2ed.com/net-connect/programmes/targeted-radiopharmaceutical-treatment-nets/?media=0

Follow us on social media:

LinkedIn: https://www.linkedin.com/company/cor2ed-net-connect/?viewAsMember=true

X: https://x.com/net_connectinfo

This content is intended for healthcare professionals only.

This podcast is supported by an Independent Education Grant from ITM.

This podcast is developed by cor2ed.com

Published September 2025

Metastatic pancreatic ductal adenocarcinoma (mPDAC) is notoriously aggressive with a poor prognosis. It is often diagnosed late, and by this time, surgery is usually not an option. Median overall survival without treatment is just a few months but with systemic chemotherapy this can be improved.

This video includes the highlights from a video podcast where medical oncologists Prof Shubham Pant and Prof Efrat Dotan discuss how to choose and optimise the different chemotherapeutic options at first and second line.

Key clinical takeaways:

• mPDAC is notoriously aggressive with a poor prognosis. Patients are generally diagnosed with advanced-stage disease and require treatment with chemotherapy as soon as possible
• Frontline regimens should be individualised based on performance status, comorbidities, and risk of neuropathy; FOLFIRINOX, NALIRIFOX, and gemcitabine/nab-paclitaxel all offer survival benefit with distinct toxicity profiles
• Choice of 2nd line treatment should be guided by prior regimen and patient fitness
• Dose modification and alternative scheduling are standard in real-world practice and are used to maintain dose intensity while improving tolerability and reducing adverse events

You can also watch a video of the experts in conversation and download the accompanying transcript on our website: https://cor2ed.com/gi-connect/programmes/tackling-mpdac/?media=0

Or watch on YouTube: https://youtu.be/8YxRnjOYUv4

Follow us on social media:

LinkedIn: https://www.linkedin.com/company/giconnect

X: https://x.com/giconnectInfo

This content is intended for healthcare professionals only.

The medical experts in this podcast are expressing their own views and not those of COR2ED, Supporters or their institution. This podcast is supported by an Independent Education Grant from Ipsen USA.

This podcast is developed by cor2ed.com

Published May 2025

Subscribe to this channel to stay up to date with new Independent Education programmes as they’re released.

Listen to a revealing conversation between Dr Joshua Sabari, a Medical Oncologist specialising in the treatment of rare alternations of NSCLC and Debra Montague, President of Lung Cancer Europe (LuCE) and founder of ALK Positive UK.

As a patient advocate as well as a patient herself, Debra brings a wealth of experience and depth of insight into the discussion with Dr Sabari.

Dr Sabari shares his clinical knowledge regarding diagnosis, biomarker testing and treatment of such alterations, together with his own first-hand experience of treating and empowerig patients like Debra in their own treatment journey.

What does the patient pathway look like from both perspectives? What are the needs of Medical Oncologists and patients when navigating the treatment journey? What do patients need from their oncologists? What do oncologists think their patients need from them? Are these needs matched by the support currently available?

You can also watch a video of the experts in conversation and download the transcript on our website: https://cor2ed.com/lung-connect/programmes/understanding-rare-nsclc-mutations/?media=0

Or watch on YouTube: https://www.youtube.com/watch?v=Z57cUtQx1BE&t

Follow LUNG CONNECT on social media:

X – https://x.com/lung_connect

LinkedIn – https://www.linkedin.com/company/lungconnect/

This content is intended for healthcare professionals only.

The experts in this podcast are expressing their own views and not those of COR2ED, Supporters or their institution. This podcast is supported by an Independent Education Grant from Boehringer Ingelheim.

This podcast is developed by cor2ed.com

Published on May 2025

Subscribe to this channel to stay up to date with new Independent Education programmes as they’re released.

Episode 2: Navigating common treatment scenarios in HER2-mutant NSCLC

This is the second episode of a two-part series on the HER2 diagnostic and treatment landscape in NSCLC, hosted by the Oncology Brothers, Drs Rohit and Rahul Gosain.

In this episode Drs Isabel Preeshagul and Eric Singhi provide the benefit of their experience when discussing how to approach different treatment scenarios in HER2-mutant NSCLC.

The conversation unfolds to cover;

• How to distinguish HER2 alterations from other alterations on biomarker reports

• The latest efficacy and safety data of currently approved and emerging treatments for HER2-altered NSCLC

• The potential CNS activity of these treatments in patients with HER2-mutated NSCLC

• How the treatment pathway may look in the near future

You can also watch a video of the experts in conversation and download the transcript on our website: https://cor2ed.com/lung-connect/programmes/her2-diagnostic-treatment-nsclc-2/

Or watch on YouTube: https://youtu.be/E8-3GDyJT9Y

Follow LUNG CONNECT on social media:

X – https://x.com/lung_connect

LinkedIn – https://www.linkedin.com/company/lungconnect/

This content is intended for healthcare professionals only.

The medical experts in this podcast are expressing their own views and not those of COR2ED, Supporters or their institution. This podcast is supported by an Independent Education Grant from Bayer.

This podcast is developed by cor2ed.com

Published on May 2025

Subscribe to this channel to stay up to date with new Independent Education programmes as they’re released.

Episode 1: Identifying HER2-directed NSCLC: The Medical Oncologist and Pathologist perspectives

This is the first episode of a two-part series on the HER2 diagnostic and treatment landscape in NSCLC, hosted by the Oncology Brothers, Drs Rohit and Rahul Gosain.

What makes this conversation so interesting, is that you can gather insights from both the Medical Oncologist perspective with Dr Devika Das, and pathology perspective from Prof. Lopéz-Ríos.

In this episode the discussion focuses identifying HER2-directed NSLC, considering mutations, overexpression and amplifications, whilst not forgetting how best practice in identification of HER2 alterations may be translated in the community setting.

Listen to different expert perspectives on

• The different HER2 alterations and prevalence in NSCLC

• Which technique to identify which HER2 alteration

• HER2-targeted treatments, both approved and in development

You can also watch a video of the experts in conversation and download the transcript on our website: https://cor2ed.com/lung-connect/programmes/her2-diagnostic-treatment-nsclc-1/?media=1

Or watch on YouTube: https://youtu.be/3vMCzR1jqbI

Follow LUNG CONNECT on social media:

X – https://x.com/lung_connect

LinkedIn – https://www.linkedin.com/company/lungconnect/

This content is intended for healthcare professionals only.

The medical experts in this podcast are expressing their own views and not those of COR2ED, Supporters or their institution. This podcast is supported by an Independent Education Grant from Bayer.

This podcast is developed by cor2ed.com

Published on April 2025

Subscribe to this channel to stay up to date with new Independent Education programmes as they’re released.

In this podcast, Dr Aditya Bardia and Dr Virginia Kaklamani share their insights on the recent publication of the subgroup analyses from the phase 3 EMERALD trial by prior duration of endocrine therapy plus CDK4/6 inhibitor and in clinical subgroups.

Key topics include

• Identifying tumors that remain endocrine-sensitive despite acquired resistance to previous ET

• Clinical implications of the EMERALD post-hoc subgroup analyses

• Review of elacestrant's safety profile

Clinical takeaways

• Duration of prior ET + CDK4/6i ≥12 months was associated with a clinically meaningful improvement in PFS for elacestrant compared with SOC endocrine monotherapy in patients with ESR1-mut, ER+/HER2– metastatic breast cancer

• The PFS benefit associated with elacestrant was consistent across clinically relevant subgroups evaluated, including patients with bone metastases, liver and/or lung metastases, n<3 or ≥3 metastatic sites or tumors with PIK3CA-mut, TP53-mut, HER2-low tumor expression, or ESR1-mut variants D538G or Y537S/N

• Safety analyses demonstrated that elacestrant had a manageable safety profile similar to other ETs and without evidence of the toxicities associated with other drug classes, such as CDK4/6i and PI3K/AKT/mTOR inhibitors

• These data support current guidelines that recommend routine testing for the emergence of ESR1-mut in ctDNA at each disease progression

This programme has been sponsored by Menarini Stemline and is intended for healthcare professionals only.

This video was developed by https://cor2ed.com/

Published March 2025